BioSpace News Archive

InsightRX, a pioneer in precision medicine, and Premier Inc., a healthcare improvement company uniting 4,000 U.S. hospitals and health systems, have joined forces to individualize medication dosing for drugs used to treat infectious disease.

Newronika, a spin-off of world-class neurological research center Policlinico of Milan and University of Milan, has appointed Dr. Oleg Svanidze MD, PhD as a Chief Medical Officer

Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York City.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended September 30, 2019.

The $6 million award, which represents new work for the company, has a one-year period of performance.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the three and nine-months ended September 30, 2019.

ELT Sight, Inc. today announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery.

EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.

Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Stifel 2019 Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 10:55 a.m. Eastern Time.

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter ending September 30, 2019.